VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | First-line regorafenib 80mg/day with pembrolizumab in advanced HCC

Anthony B. El-Khoueiry, MD, Keck School of Medicine of USC, Los Angeles, CA, discusses highlights from the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2021, including the results of an ongoing Phase Ib study of regorafenib 80 mg/day plus pembrolizumab for first-line treatment of advanced hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter